Amaral R, dos Santos S, Andrade L, Severino P, Carvalho A. Natural Products as Treatment against Cancer: A Historical and Current Vision. Clin Oncol (R Coll Radiol) 2019; 4: 1562.
Mousa SA, Sudha T, Davis PJ. Anti-angiogenesis therapy and its combination with chemotherapy: impact on primary tumor and its metastasis anti-angiogenesis strategies in cancer therapeutics. Elsevier 2017; pp. 147-63.
Schoffski P, Casali P, Taron M, Van Oosterom A, Judson I, Grosso F, et al. DNA repair functionality modulates the clinical outcomeof patients with advanced sarcoma treated with trabectedin (ET- 743). Journal of Clinical Oncology 2006; 24(18_suppl): 9522.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. cell 2011; 144(5): 646-74.
McAlpine JN, Porter H, Kobel M, Nelson BH, Prentice LM, Kalloger SE, et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Modern pathology: an official journal of the United States and Canadian Academy of Pathology. Inc 2012; 25(5): 740-50.
Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 23(9): 1867-74.
Sanctis R De, Marrari A, Marchetti S, et al. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma. Drug design, development and
therapy 2015; 9: 5785-91.
Pompili L, Leonetti C, Biroccio A, Salvati E. Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option? Journal of experimental & clinical cancer research. CR (East Lansing Mich) 2017; 36(1): 189.